
Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

EU COVID-19 antibody ready for clinical trials
CORAT Therapeutics reports the start of production of the first batch of the therapeutic human COVID-19 antibody COR-101 for Phase I testing....

Evotec expanding at Milton Park campus
According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

European Circular Bioeconomy Fund growing
Nurition world market leader Nestlé as well as Neste Oyj, Volkswohl Bund Versicherungen, NRW.BANK and an undisclosed family office contributed to the...

Novo Holdings creates Hemab
Hemab ApS will combine antibody know-how from Genmab A/S and Novo Nordisk to fight medically underserved orphan bleeding disorders. The company...

Priothera closes €30m Series A financing
The Irish cancer specialist Priothera Limited said it will use the the proceed sto advance its S1P receptor modulator mocravimod to Ohase...